Drug Profile


Alternative Names: ALD-403

Latest Information Update: 10 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Alder Biopharmaceuticals
  • Class Antimigraines; Monoclonal antibodies
  • Mechanism of Action Calcitonin gene-related peptide antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Migraine

Most Recent Events

  • 07 Nov 2017 Alder announces intention to submit BLA to US FDA for Migraine (Prevention) in second half of 2018
  • 07 Nov 2017 Alder Biopharmaceuticals completes enrolment in its phase III PROMISE 2 trial for Migraine (Prevention) in Georgia, Ukraine, Spain, Slovakia, Russia, Italy, Hungary, Germany, Denmark, Czech Republic, Belgium, United Kingdom and USA
  • 27 Jun 2017 Efficacy data from the phase III PROMISE 1 trial in Migraine released by Alder BioPharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top